Cytokine production at the site of disease in chronic eosinophilic pneumonitis

American Journal of Respiratory and Critical Care Medicine

Volumn 153, Issue 4, 1996, Pages 1437-1441

  Kita, Hirohito ^a   Sur, Sanjiv ^b   Hunt, Loren W ^b   Edell, Eric S ^b   Weiler, Debbie A ^b   Swanson, Mark C ^b   Samsel, Richard W ^b   Abrams, John S ^b   Gleich, Gerald J ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD; CASE REPORT; CELL SURVIVAL; CONTROLLED STUDY; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; LOEFFLER PNEUMONIA; LUNG LAVAGE; PRIORITY JOURNAL;

EID: 0029947503     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.153.4.8616578     Document Type: Article

References (20)

1. Carrington, C. B., W. W. Addington, A. M. Goff, I. M. Madoff, A. Marks, J. R. Achwaber, and E. A. Gaensler. 1969. Chronic eosinophilic pneumonia. N. Engl. J. Med. 280:787-798.
2. Jederlinic, P. J., L. Sicilian, and E. A. Gaensler. 1988. Chronic eosinophilic pneumonia: a report of 19 cases and a review of the literature. Medicine 67:154-162.
3. Pesci, A., G. Bertorelli, P. Manganelli, P. A. Mori, F. Strinati, E. Marangio, and D. Olivieri. 1988. Bronchoalveolar lavage in chronic eosinophilic pneumonia. Respiration 54(Suppl. 1):16-22.
4. Gonzalez, E. B., J. L. Swedo, S. Rajarama, J. C. Daniels, and J. A. Grant. 1987. Ultrastructural and immunohistological evidence for release of eosinophilic granules in vivo: cytotoxic potential in chronic eosinophilic pneumonia. J. Allergy Clin. Immunol. 79:755-762.
5. Gaensler, E. A., and C. B. Carrington. 1977. Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary edema. AJR 128:1-13.
6. Mayo, J. R., N. L. Muller, J. Road, J. Sisler, and G. Lillington. 1989. Chronic eosinophilic pneumonia: CT findings in six cases. AJR 153:727-730.
7. Hansel, T. T., I. J. M. De Vries, M. T. Iff, S. Rihs, M. Wandzilak, S. Betz, K. Blazer, and C. Walker. 1991. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J. Immunol. Methods 145:105-110.
8. Ohnishi, T., H. Kita, D. A. Weiler, J. B. Sedgwick, W. J. Calhoun, W. W. Busse, J. S. Abrams, and G. J. Gleich. 1993. IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late phase reaction. Am. Rev. Respir. Dis. 147:901-907.
9. Orme, I. M., A. D. Roberts, J. P. Griffin, and J. S. Abrams. 1993. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J. Immunol. 151:518-525.
10. Hamid, Q., J. Barkans, Q. Meng, S. Ying, J. S. Abrams, A. B. Kay, and R. Moqbel. 1992. Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood 80:1496-1501.
11. Sieling, P. A., J. S. Abrams, M. Yamamura, P.Salgame, B. R. Bloom, T. H. Rea, and R. L. Modlin. 1993. Immunosuppressive roles for IL-10 and IL-4 in human infection. J. Immunol. 150:5501-5510.
12. Nakamura, Y., T. Ozaki, T. Kamei, K. Kawaji, K. Banno, S. Mikki, K. Fujisawa, S. Yasuoka, and T. Ogura. 1993. Factors that stimulate the proliferation and survival of eosinophils in eosinophilic pleural effusion: relationship to granulocyte/macrophage colony-stimulating factor, interleukin-5, and interleukin-3. Am. J. Respir. Cell Mol. Biol. 8:605-611.
13. Matsumoto, R., M. Ando, H. Kohrogi, S. Araki, and K. Takatsu. 1992. Interleukin-5 levels of pleural fluid and serum samples in a patient with PIE syndrome. Chest 102:1296-1297.
14. Walker, C., W. Bauer, R. K. Braun, G. Menz, P. Braun, F. Schwarz, T. T. Hansel, and B. Villiger. 1994. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am. J. Respir. Crit. Care Med. 150:1038-1048.
15. Weller, P. F. 1991. The immunobiology of eosinophils. N. Engl. J. Med. 324:1110-1118.
16. Lopez, A. F., C. J. Sanderson, J. R. Gamble, M. D. Campbell, J. G. Young, and M. A. Vadas. 1988. Recombinant human interleukin-5 is a selective activator of human eosinophil function. J. Exp. Med. 167:219-224.
17. Rothenberg, M. E., J. P. Peterson, R. L. Stevens, D. S. Silberstein, D. T. McKenzie, K. F. Austen, and W. F. Owen, Jr. 1989. IL-5 dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. J. Immunol. 143:2311-2316.
18. Wang, J. M., A. Rambaldi, A. Biondi, Z. G. Chen, C. J. Sanderson, and A. Mantovani. 1989. Recombinant human interleukin-5 is a selective activator of human eosinophil function. Eur. J. Immunol. 19:701-705.
19. Walsh, G. M., A. Hartnell, A. J. Wardlaw, K. Kurihara, C. J. Sanderson, and A. B. Kay. 1990. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leukocyte integrin (CD11/18)-dependent manner. Immunology 71:258-265.
20. Ebisawa, M., M. C. Liu, T. Yamada, M. Kato, L. M. Lichtenstein, B. S. Bochner, and R. P. Schleimer. 1994. Eosinophil transendothelial migration induced by cytokines. II. Potentiation of eosinophil transendothelial migration by eosinophil-active cytokines. J. Immunol. 152:4590-4596.